This Government Contract opportunity from Department Of Health And Human Services was posted on April 23, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Synthetic Specimen Matrix Development and Validation

Closed

Federal

Submission Closed05/22/2026, 02:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414

New

Federal

65--Methylation Sequencing Library Preparation Kits fo

Solicitation # 75N98026Q01200

The National Heart, Lung, and Blood Institute (NHLBI) within the Department of Health and Human Services is pursuing a single-source, non-competitive acquisition for Integrated DNA Technologies (IDT) methylation sequencing library preparation kits. This procurement, conducted under FAR Part 13 Simplified Acquisition Procedures, supports research on cell-free DNA methylation profiles in organ transplant recipients to identify signatures related to organ injury and allograft status. The government has specified brand-name IDT products to ensure high-quality, reproducible next-generation sequencing results by minimizing adapter and primer dimer formation. The requirement consists of 12 xGen Methyl-Seq Library Prep kits, 6 xGen 2S Plus DNA Library Prep kits, and 1 xGen UDI 10nt Primer Plates kit, with a total estimated cost of 77,117.11 including shipping and handling. While the government intends to award a non-competitive contract, interested parties were invited to demonstrate their bona-fide capability by September 14, 2026. Submissions must include pricing, delivery timelines, F.O.B. points, and administrative data such as UEI and TIN, while maintaining active registration in the System for Award Management (SAM). The action is categorized under NAICS code 325414.

National Institutes Of Health Nhlbi

POSTED

DEADLINE

Vivo Efficacy of Blood stable Thiobenzamides 

Solicitation # 75N98026Q01123

Solicitation 75N98026Q01123 is a combined synopsis and solicitation issued by the National Institutes of Health Office of the Director under the Department of Health and Human Services. The contract seeks the procurement of services to evaluate the vivo efficacy of blood stable Thiobenzamides. The scope of work encompasses the use of mouse disease models, BSL-3 viral load monitoring, immunophenotyping, and comprehensive project management. This acquisition is structured as a Firm-Fixed-Price contract for commercial items in accordance with FAR 12.6, falling under NAICS code 325414. The performance of the contract is centered in Bethesda, Maryland. Interested parties must submit their responses by the deadline of September 20, 2026.

National Institutes Of Health Olao

POSTED

DEADLINE

ACAN Vaccinia Immunoglobulin intravenous (human) - VIGIV

Solicitation # WS5872093541

Public Services and Procurement Canada, acting on behalf of the Public Health Agency of Canada, has issued an Advanced Contract Award Notice for the procurement of Vaccinia Immunoglobulin intravenous (human), known as VIGIV. This medical product is required to protect against complications arising from vaccinations with live-replicating smallpox vaccines containing the vaccinia virus. The government intends to negotiate a contract with Emergent BioSolutions Canada Inc, provided no other qualified suppliers express interest. The solicitation, identified by number WS5872093541, was posted on September 10, 2026, with a response deadline of September 30, 2026. Other potential suppliers may submit a statement of capabilities by this date to challenge the pre-identified award. The contract is managed by the Department of Public Works and Government Services for performance within Canada.

Department of Public Works and Government Services

POSTED

DEADLINE

Specialty Medical Consumables SupplyThe Specialty Medical Consumables Supply subcontract, issued by the Southern Regional Health Authority under the Government of Jamaica, facilitates the procurement of essential medical supplies. This agreement focuses on the provision of specialized items, including surgical drapes, sterile kits, catheters, and various infection control products. The primary purpose of this contract is to ensure a continuous supply of these critical materials in instances where the demand exceeds the existing inventory held by the prime contractor. Classified under NAICS code 325414, which pertains to pharmaceutical and medical manufacturing, this subcontract is designed to maintain operational readiness within the regional health system. The contract was officially posted on August 22, 2026, and serves as a strategic mechanism to mitigate supply chain risks by providing a secondary source for high-demand medical consumables. Interested parties can access further details and procurement documentation through the official electronic procurement portal provided by the government.

Southern Regional Health Authority

POSTED

DEADLINE

Medical Diagnostic Test Kit SupplyThe Defense Logistics Agency under the Department of Defense has issued a subcontract for the supply of 100 E. coli detection test kits. These diagnostic kits must strictly adhere to FDA regulations, specific shelf-life requirements, and Department of Defense medical packaging standards to ensure quality and viability. Classified under NAICS code 325414, this procurement focuses on the delivery of specialized medical diagnostic tools. The contract was posted on August 11, 2026, and is managed through the DLA's acquisition systems to support military medical readiness.

Defense Logistics Agency

POSTED

DEADLINE

Medical Supply Procurement – Petrolatum GauzeThis subcontract with the Defense Logistics Agency under the Department of Defense involves the manufacture or supply of 27 units of petrolatum gauze, identified by NSN 6510-01-112-6414. The procurement falls under NAICS code 325414 and requires all units to meet strict military medical standards. Key delivery requirements include a minimum shelf life of 36 months, with a mandate that the time elapsed from manufacture to delivery does not exceed five months. The contract was posted on August 10, 2026.

Defense Logistics Agency

POSTED

DEADLINE

Typhoid Vi Polysaccharide Vaccine SupplyThis subcontract through the Defense Logistics Agency under the Department of Defense involves the supply of 1,000 units of FDA-compliant, preserved Typhoid Vi Polysaccharide Vaccine. The procurement is categorized under NAICS code 325414 and is designated for delivery to a U.S. Navy vessel. The agreement is established under FOB Destination terms, ensuring the delivery of the medical supplies to the specified naval location. The contract was posted on August 10, 2026, and is managed via the DIBBS system.

Defense Logistics Agency

POSTED

DEADLINE

Supply and Delivery of Typhoid VI Polysaccharide Vaccine (NSN 6505015334962)This subcontract with the Defense Logistics Agency involves the procurement, packaging, and delivery of 1,000 units of preservative-free Typhoid VI Polysaccharide Vaccine. The product must comply with NDC 49281-0790-51 and NSN 6505015334962. The vaccines are to be delivered to the USS Theodore Roosevelt (CVN 71) at FPO AP 96632 by August 10, 2026. Shipping must be handled via FOB Destination using fast and traceable methods to ensure secure arrival.

Defense Logistics Agency

POSTED

DEADLINE

MMR Vaccine Supply and Delivery

Defense Logistics Agency

POSTED

DEADLINE

Pharmaceutical Product Supply – Aluminum Hydroxide Gel

Defense Logistics Agency

POSTED

DEADLINE

Measles, Mumps, and Rubella (MMR) Vaccine Supply and DeliveryThe contract entails the supply and delivery of three units of Measles, Mumps, and Rubella vaccine to a U.S. Navy vessel at a forward operating base destination, with strict requirements for traceable express shipping and full compliance with established medical handling standards. The contractor is responsible for ensuring the vaccines remain viable throughout transit by adhering to temperature control, packaging, and documentation protocols mandated for biological materials. This is a subcontract under the Department of Defense, managed by the Defense Logistics Agency, with a NAICS code of 325414 indicating pharmaceutical preparation manufacturing. The delivery must be completed in accordance with military logistics guidelines, and all shipping records must maintain a verifiable chain of custody from origin to final receipt aboard the vessel. The contract was posted on August 9, 2026, and the place of performance is tied to a military operational location, though specific geographic details are not provided. The award reference number SPE2DX25D8022 and delivery identifier SPE2D926F8119 are linked to the official DLA procurement system, underscoring the mission-critical nature of timely and secure delivery. While the solicitation number is not listed, the subcontract structure suggests coordination with a prime contractor to fulfill the DOD’s medical readiness requirements. All activities must comply with federal regulations governing vaccine distribution and military supply chain integrity.

Defense Logistics Agency

POSTED

DEADLINE

Supply of Tetanus and Diphtheria Toxoids, Adsorbed Vaccine

Defense Logistics Agency

POSTED

about 1 month ago

DEADLINE

N/A

AI Contract Overview

The contract seeks the development and production of synthetic specimen matrices, such as synthetic blood and saliva, specifically designed for use in the development and validation of diagnostic tests. These matrices must meet FDA validation standards to ensure authenticity and reliability in laboratory settings, supporting accurate test performance evaluation without the use of human biological samples. The work is classified under NAICS code 325414, indicating a focus on pharmaceutical and medicinal chemistry manufacturing, and requires precise formulation, quality control, and documentation to align with regulatory requirements for diagnostic applications. The opportunity is issued as a subcontract by the CDC Office of Acquisition Services under the Department of Health and Human Services, with performance expected to be centered in Atlanta, Georgia, 30341. The solicitation was posted on April 23, 2026, and responses are due by May 22, 2026, at 2:00 PM Eastern Time. While no set-aside provisions or special certifications are specified, the requirement demands technical expertise in synthetic biomaterials and experience navigating FDA validation frameworks. Proposers must demonstrate capability to deliver scalable, consistent, and validated products that enable reliable diagnostic test development, with an emphasis on reproducibility and regulatory compliance.

General Info

Develop and produce FDA-validated synthetic blood and saliva for diagnostic test validation.

Agency

Department Of Health And Human Services → CDC Office Of Acquisition ServicesView Agency

NAICS

325414 - Biological Product (except Diagnostic) ManufacturingView NAICS

Place of Performance

GA, 30341, USA

Set-Aside

NONE

Documents

This scope was carved out of 412026.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Request for Information on CDC Procurement of Clinical Specimens

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedApr 23

subcontract

Response DeadlineMay 22

Deadline has passed

Submission Closed

05/22/2026, 02:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → CDC Office Of Acquisition Services

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Health And Human Services → CDC Office Of Acquisition Services

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Development and production of FDA-validated synthetic specimen matrices (e.g., synthetic blood, saliva) for diagnostic test development and validation.